https://scholars.lib.ntu.edu.tw/handle/123456789/638380
標題: | Occult hepatitis B infection | 作者: | TAI-CHUNG TSENG CHUN-JEN LIU |
關鍵字: | Direct-acting antiviral | Epidemiology | HCC | Hepatitis C | Immunosuppression | Occult hepatitis B | Prevention | Reactivation | Transfusion | 公開日期: | 23-八月-2021 | 來源出版物: | Hepatitis B Virus and Liver Disease | 摘要: | Occult hepatitis B virus infection (OBI) is defined as the presence of HBV replicative templates in the liver with/without circulating HBV DNA in patients with undetectable hepatitis B surface antigen (HBsAg). The prevalence of OBI is estimated to be ranging from <1 to 18% in general population. Usually, serum HBV DNA level is low and intermittently detected, which does not induce liver damage. However, there are some potential risk for patients. Firstly, OBI has been reported to be associated with the development HCC in patients with chronic hepatitis C in some studies, but other studies did not find such an association. It is still a debating issue whether OBI may accelerate the disease progression toward cirrhosis and the development of HCC in patients with other chronic liver diseases. Secondly, there is potential risk of HBV transmission through blood transfusion from OBI donors. The risk could be minimized by screening the blood products using nucleic acid testing. Thirdly, HBV reactivation from OBI is being increasingly recognized when patients receive potent immune-suppressive therapies including B-cell depleting agents. Although prophylactic antiviral therapy minimizes the risk of HBV reactivation, the best strategy to prevent HBV reactivation in these situations remains to be defined. More research is needed to develop a useful guideline to optimize clinical management of OBI. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638380 | ISBN: | 9789811636158 | DOI: | 10.1007/978-981-16-3615-8_17 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。